Summarizing efficacy data on tirzepatide, a novel glucose-lowering dual GIP/GLP-1 receptor agonist
What you need to know
The novel type 2 diabetes medication tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Its efficacy is being tested in the phase 3 SURPASS clinical trial program, with results of the cardiovascular outcomes study and a trial of tirzepatide in people with obesity but without diabetes expected in 2024. Explore this page for trial results and expert commentary, updated as new results are reported.
SURPASS-1 trial results & series summary
Trial series summary and independent commentary provided by John Wilding, University of Liverpool.
The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.
Researcher commentary provided by Juan Pablo Frías, National Research Institute, Los Angeles, USA
People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.
Researcher commentary provided by Francesco Giorgino, University of Bari Aldo Moro, Italy.
The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.
Researcher commentary provided by Michelle Welch, Diabetes and Metabolism Specialists, San Antonio, Texas, USA.
People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.
Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
